Capital Asset Advisory Services LLC Sells 3,033 Shares of Astrazeneca Plc $AZN

Capital Asset Advisory Services LLC lessened its stake in shares of Astrazeneca Plc (NYSE:AZN) by 56.8% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,303 shares of the company’s stock after selling 3,033 shares during the period. Capital Asset Advisory Services LLC’s holdings in Astrazeneca were worth $462,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of AZN. Brighton Jones LLC grew its stake in shares of Astrazeneca by 93.2% in the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after buying an additional 2,789 shares during the period. AQR Capital Management LLC boosted its holdings in Astrazeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after acquiring an additional 11,690 shares in the last quarter. Amundi boosted its holdings in Astrazeneca by 54.4% in the second quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after acquiring an additional 3,618 shares in the last quarter. Jump Financial LLC grew its stake in Astrazeneca by 898.4% in the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock valued at $2,339,000 after acquiring an additional 30,125 shares during the period. Finally, Daiwa Securities Group Inc. grew its stake in Astrazeneca by 1.2% in the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after acquiring an additional 559 shares during the period. 20.35% of the stock is owned by institutional investors.

Astrazeneca Stock Up 6.0%

Shares of NYSE:AZN opened at $194.96 on Friday. The stock has a market cap of $302.36 billion, a price-to-earnings ratio of 29.27, a PEG ratio of 1.49 and a beta of 0.24. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The business’s 50 day moving average is $183.91 and its 200 day moving average is $187.76.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. On average, sell-side analysts forecast that Astrazeneca Plc will post 10.28 earnings per share for the current fiscal year.

Astrazeneca News Summary

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
• Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
• Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
• Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
• Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Bank of America reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Tuesday. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Fourteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Astrazeneca currently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.